LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Editas Medicine Inc

Editas Medicine Inc

Gesloten

SectorGezondheidszorg

2.76 3.37

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.73

Max

2.76

Belangrijke statistieken
By Trading Economics
Inkomsten	-19M -25M
Verkoop	-22M 2.8M
EPS	-0.26
Winstmarge	-882.444
Werknemers	87
EBITDA	-19M -25M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+139.13% upside

Dividenden
By Dow Jones
Volgende Winsten	10 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-52M 241M
Vorige openingsprijs	-0.61
Vorige sluitingsprijs	2.76

Nieuwssentiment

By Acuity

50%

146 / 345 Rangschikking in Healthcare

Editas Medicine Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 mei 2026, 23:46 UTC

Marktinformatie

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 mei 2026, 23:45 UTC

Marktinformatie

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 mei 2026, 23:42 UTC

Marktinformatie

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 mei 2026, 23:34 UTC

Marktinformatie

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 mei 2026, 23:11 UTC

Marktinformatie

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 mei 2026, 22:26 UTC

Acquisities, Fusies, Overnames

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 mei 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 mei 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 mei 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 mei 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 mei 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 mei 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 mei 2026, 22:11 UTC

Marktinformatie

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 mei 2026, 22:04 UTC

Marktinformatie

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 mei 2026, 08:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

23 mei 2026, 08:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

22 mei 2026, 21:10 UTC

Winsten

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 mei 2026, 19:47 UTC

Winsten

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mei 2026, 19:17 UTC

Marktinformatie

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mei 2026, 19:10 UTC

Marktinformatie

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mei 2026, 18:38 UTC

Marktinformatie

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mei 2026, 18:35 UTC

Acquisities, Fusies, Overnames

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mei 2026, 18:09 UTC

Marktinformatie

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mei 2026, 17:58 UTC

Marktinformatie

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Peer Vergelijking

Prijswijziging

Editas Medicine Inc Prognose

Koersdoel

By TipRanks

139.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.6 USD 139.13%

Hoogste 15 USD

Laagste 4 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Editas Medicine Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Editas Medicine Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

146 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.